Biofilm Pharma

Platinum Sponsor

BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for Health Care system in high-income countries ($4 billions). BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy. We have already 45 compound families (Small molecules, NCE) in our pipeline and are 3 years up to proof-of-concept in patients for potential blockbusters.